Acrivon Therapeutics, Inc. Common Stock
USD1.75
+0.01 (+0.57%)
CEO
Peter Blume-Jensen
IPO Date
2022-11-15
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
Open
$1.75
Prev. Close
$1.74
Day Low
$1.73
Day High
$1.77
52W Low
$1.20
52W High
$3.56
Market Cap
$0.06B
Volume
0.12M
| 20,275 |
| $1.52 |
| 22 Jun 2026 | Palani Santhosh | director | A-Award | Acquired | 20,275 | $1.52 |
| 22 Jun 2026 | Magovcevic-Liebisch Ivana | director | A-Award | Acquired | 20,275 | $1.52 |
| 22 Jun 2026 | DiRocco Derek | director | A-Award | Acquired | 20,275 | $1.52 |
| 22 Jun 2026 | BAUM CHARLES M | director | A-Award | Acquired | 20,275 | $1.52 |
| 22 Jun 2026 | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | A-Award | Acquired | 20,275 | $1.52 |
| 26 May 2026 | Blume-Jensen Peter | director, officer: President and CEO | F-InKind | Disposed | 13,729 | $1.79 |
| 20 May 2026 | Blume-Jensen Peter | director, officer: President and CEO | A-Award | Acquired | 72,706 | $0.00 |
| 20 May 2026 | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | A-Award | Acquired | 9,366 | $0.00 |